- Category: Imagine institute news
- Published: Tuesday, 18 July 2017 14:47
On July 17, 2017, the French Prime Minister announced the launch of the first two genome sequencing platforms in France. As part of the France Médecine Génomique 2025 plan (French Plan for Genomic Medicine), “these two platforms will be able to sequence and interpret the equivalent of 18,000 genomes per year, thus taking another step towards making personalized medicine accessible to all French people.” Two projects have been selected for implementing this plan, one of which is the Seqoia project, led by the Greater Paris University Hospitals (AP-HP), Institut Curie, Institut Gustave-Roussy and Imagine Institute.
Stanislas Lyonnet, Director of the Institute, welcomes this decision and the commitment of Imagine Institute and its three public founding members (AP-HP, Inserm and Paris Descartes University) to the Seqoia project. “As emphasized by the Prime Minister, this branch of medicine “holds great promise”. France Médecine Génomique 2025 will contribute directly to the understanding, diagnosis and treatment of many genetic diseases. As a reminder, there is still no cure for 98% of such conditions. The collaboration of the majority of public genome institutions in Île-de-France will be a major advantage in addressing this considerable public health issue.
The acceleration of genomic medicine through the sharing of cutting-edge, scalable platforms involves and impacts Imagine significantly. Both in terms of research, particularly in exploring and especially interpreting noncoding DNA, deploying bioinformatics and high-speed data management, and in medico-economic terms.
Indeed, our health sovereignty in the field of genomic medicine is dependent on managing the instruction and interpretation of next-generation targeted sequencing data. It is not the data that counts, but rather what we can learn from it through the essential comparison of clinical and laboratory experience. And it is by remaining faithful to the aim of improving care for patients with genetic diseases that we will practice the best medicine today, and invent the personalized medicine of tomorrow.”